EBIT at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's EBIT?
- Kymera Therapeutics (KYMR) reported EBIT of -$84.15M in Q1 2026.
- How has Kymera Therapeutics's EBIT changed year-over-year?
- Kymera Therapeutics's EBIT decreased by 13.1% year-over-year, from -$74.43M to -$84.15M.
- What is the long-term trend for Kymera Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Kymera Therapeutics's EBIT has grown at a 36.5% compound annual growth rate (CAGR), from -$100.53M to -$349.4M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.